Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1878 Target Snapshot

Extracellular calcium-sensing receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
675Compounds
44Assays
2Approved Drugs
711.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Extracellular calcium-sensing receptor shows approved-linked disease relevance led by secondary hyperparathyroidism. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P41180. Start with secondary hyperparathyroidism, then reuse UniProt P41180 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with secondary hyperparathyroidism, then reuse UniProt P41180 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 5 linked drugs
Open source guide
Disease program
secondary hyperparathyroidism

Extracellular calcium-sensing receptor shows approved-linked disease relevance led by secondary hyperparathyroidism. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.

Start review with secondary hyperparathyroidism because it currently carries approved-linked support. Linked drugs include ASP7991, CINACALCET HYDROCHLORIDE, ETELCALCETIDE, ETELCALCETIDE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 5 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Extracellular calcium-sensing receptor as ChEMBL target CHEMBL1878, mapped to UniProt P41180. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Extracellular calcium-sensing receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1878
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P41180
Extracellular calcium-sensing receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Extracellular calcium-sensing receptor is the right protein anchor across sources, using UniProt P41180 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why secondary hyperparathyroidism is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameExtracellular calcium-sensing receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP41180
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelExtracellular calcium-sensing receptor
UniProt AccessionP41180
Component TypeProtein
Sequence Length1078 aa

Extracellular calcium-sensing receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Extracellular calcium-sensing receptor, mapped to UniProt P41180. Sequence length is 1078 aa.

Mapped IDP41180
Review nameExtracellular calcium-sensing receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Extracellular calcium-sensing receptor shows approved-linked disease relevance led by secondary hyperparathyroidism. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
secondary hyperparathyroidism
5 linked drugs · 5 direct · 5 efficacy
Linked drugASP7991
Linked drugCINACALCET HYDROCHLORIDE
Linked drugETELCALCETIDE
Linked drugETELCALCETIDE HYDROCHLORIDE
Approved-linked Approved
chronic kidney disease
3 linked drugs · 3 direct · 3 efficacy
Linked drugCINACALCET HYDROCHLORIDE
Linked drugETELCALCETIDE
Linked drugETELCALCETIDE HYDROCHLORIDE
Approved-linked Approved
hyperparathyroidism
2 linked drugs · 2 direct · 2 efficacy
Linked drugCINACALCET HYDROCHLORIDE
Linked drugEVOCALCET
Approved-linked Approved
parathyroid disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugETELCALCETIDE
Linked drugEVOCALCET
Approved-linked Approved
carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugCINACALCET HYDROCHLORIDE
Approved-linked Approved
Hypercalcemia
1 linked drug · 1 direct · 1 efficacy
Linked drugCINACALCET HYDROCHLORIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with secondary hyperparathyroidism because it currently carries approved-linked support. Linked drugs include ASP7991, CINACALCET HYDROCHLORIDE, ETELCALCETIDE, ETELCALCETIDE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasesecondary hyperparathyroidism
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
2
Phase III
5
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC50417.0
EC50294.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL382741 10.74 IC50 0.018 Preclinical
CHEMBL570593 10.66 IC50 0.022 Preclinical
CHEMBL1204009 10.47 IC50 0.034 Preclinical
CHEMBL180672 10.24 IC50 0.058 Preclinical
CHEMBL597397 9.4 IC50 0.4 Preclinical
CHEMBL1689060 9.03 IC50 0.94 Preclinical
CHEMBL597800 8.85 IC50 1.4 Preclinical
CHEMBL1223714 8.8 IC50 1.6 Preclinical
CHEMBL591240 8.8 IC50 1.6 Preclinical
CHEMBL1689051 8.77 IC50 1.7 Preclinical
Distribution

pChEMBL Value Distribution

43
5.0
82
5.5
97
6.0
127
6.5
102
7.0
80
7.5
60
8.0
26
8.5
2
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

CINACALCET
CHEMBL1201284
Approved 2004
Properties Compare Identifier
CINACALCET HYDROCHLORIDE
CHEMBL1200776
Approved 2004
Properties Compare Identifier
Assay Landscape

Assay Landscape

44
Total Assays
471
Tested Compounds
2
Assay Types
Functional — 32 assays, 471 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 26 384 7.0
single protein format 4 18 6.4
assay format 2 69 6.7
Binding — 12 assays, 144 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 6 101 6.2
single protein format 6 43 7.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine